U.S. patent application number 09/858929 was filed with the patent office on 2001-10-04 for use of pyrethroid compounds to promote hair growth.
Invention is credited to Dotto, Gianpaolo, Fujii, Seishiro, Seki, Toshihiko.
Application Number | 20010027213 09/858929 |
Document ID | / |
Family ID | 22326188 |
Filed Date | 2001-10-04 |
United States Patent
Application |
20010027213 |
Kind Code |
A1 |
Seki, Toshihiko ; et
al. |
October 4, 2001 |
Use of pyrethroid compounds to promote hair growth
Abstract
A method of promoting hair growth which includes administering
to a subject an effective amount of a pyrethroid. A composition
having a pyrethroid and a pharmaceutically acceptable carrier for
promoting hair growth is also described.
Inventors: |
Seki, Toshihiko;
(Kanagawa-Ken, JP) ; Fujii, Seishiro; (Boston,
MA) ; Dotto, Gianpaolo; (Boston, MA) |
Correspondence
Address: |
Louis Myers
Fish & Richardson P.C.
225 Franklin Street
Boston
MA
02110-2804
US
|
Family ID: |
22326188 |
Appl. No.: |
09/858929 |
Filed: |
May 16, 2001 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
09858929 |
May 16, 2001 |
|
|
|
09444420 |
Nov 19, 1999 |
|
|
|
60109171 |
Nov 20, 1998 |
|
|
|
Current U.S.
Class: |
514/520 ;
514/531; 514/65 |
Current CPC
Class: |
A61K 8/40 20130101; A61P
17/14 20180101; A61Q 7/00 20130101; Y10S 514/88 20130101; A61K
31/277 20130101 |
Class at
Publication: |
514/520 ; 514/65;
514/531 |
International
Class: |
A61K 031/215 |
Claims
What is claimed is:
1. A method of promoting hair growth comprising administering to a
subject an effective amount of a pyrethroid.
2. The method of claim 1, wherein the pyrethroid is a type I
pyrethroid.
3. The method of claim 1, wherein the pyrethroid is a type II
pyrethroid.
4. The method of claim 1, wherein the pyrethroid is cypermethrin,
deltamethrin, or fenvalerate.
5. The method of claim 1, wherein the pyrethroid is administered
topically.
6. The method of claim 1, wherein the pyrethroid is provided in a
sterile composition.
7. The method of claim 6, wherein the weight percent of the
pyrethroid ranges from 0.005% to 5%.
8. The method of claim 7, wherein the weight percent of the
pyrethroid ranges from 0.01% to 2%.
9. A method of promoting hair growth comprising administering to a
subject an effective amount of a compound of the formula: 7in which
each of R.sup.a, R.sup.b, R.sup.c, and R.sup.d, independently, is
H, fluoro, chloro, bromo, iodo, or C.sub.1-4 alkyl; R.sup.2 is CN
or C.ident.CH; and R.sup.3 is 8in which X is O, S, NH, or CH.sub.2;
and each of R' and R", independently, is H, fluoro, chloro, bromo,
iodo, or C.sub.1-4 alkyl; or a salt thereof.
10. The method of claim 9, wherein said compound is administered
topically.
11. The method of claim 9, wherein said compound is provided in a
sterile composition.
12. The method of claim 9, wherein R.sup.2 is CN.
13. The method of claim 12, wherein R.sup.1 is 9in which each of
R.sup.a, R.sup.b and R.sup.c, independently, is H, fluoro, chloro,
bromo, iodo, or C.sub.1-4 alkyl.
14. The method of claim 13, wherein each of R.sup.a and R.sup.b,
independently, is chloro or bromo; and R.sup.c is H.
15. The method of claim 14, wherein each of R.sup.a and R.sup.b,
independently, is chloro.
16. The method of claim 15, wherein X is O; and each of R' and R",
independently, is H.
17. The method of claim 14, wherein each of R.sup.a and R.sup.b,
independently, is bromo.
18. The method of claim 17, wherein X is O; and each of R' and R",
independently, is H.
19. The method of claim 12, wherein R.sup.1 is 10in which R.sup.d
is H, fluoro, chloro, bromo, iodo, or C.sub.1-4 alkyl.
20. The method of claim 19, wherein R.sup.d is chloro.
21. The method of claim 20, wherein X is O; and each of R' and R",
independently, is H.
22. The method of claim 12, wherein X is O.
23. The method of claim 22, wherein each of R' and R",
independently, is H.
24. A composition for promoting hair growth comprising a pyrethroid
and a pharmaceutically acceptable carrier.
25. The composition of claim 24, wherein the pyrethroid is a type I
pyrethroid.
26. The method of claim 24, wherein the pyrethroid is a type II
pyrethroid.
27. The method of claim 24, wherein the pyrethroid is cypermethrin,
deltamethrin, or fenvalerate.
28. The composition of claim 24, said composition being
sterile.
29. The composition of claim 24, further comprising a
fragrance.
30. The composition of claim 24, wherein the weight percent of the
pyrethroid ranges from 0.005% to 5%.
31. The composition of claim 30, wherein the weight percent of the
pyrethroid ranges from 0.01% to 2%.
Description
BACKGROUND OF THE INVENTION
[0001] Unwanted hair loss can plague both men and women of all
ages. It can arise as the result of a variety of underlying causes,
including hormonal imbalance, genetic predisposition and exposure
to toxic substances. Alopecia areata is a non-scarring inflammatory
hair loss disease that can affect men, women, and even children.
The factors that activate the onset of alopecia and the mechanisms
of its development are not well understood. It is characterized
clinically by the sudden appearance of a round or oval patch of
non-scarring and painless hair loss with spontaneous remissions and
exacerbations (Weitzer, Am. Fam. Physician 41(4) :1197-1201
(1990)). The annual incidence of alopecia areata is approximately 2
per 10,000 population. 5% to 10% of patients, especially children,
result in a total loss of all of the scalp hair (alopecia totalis).
Although the disease itself is non-life threatening, the cosmetic
and psychological impact on both patients and parents is
tremendous. Patients usually suffer from a higher than normal rate
of major depression and/or other anxiety disorder (Colon et al.,
Comprehensive Psychiatry 32(3): 245-251 (1991); Beard, J. Am. Acad.
Dermatol. 14(4):697-700 (1986)).
SUMMARY OF THE INVENTION
[0002] In general, the invention features, a method of promoting
hair growth. The method includes administering to a subject, e.g.,
a human with an insufficient amount of hair or an insufficient rate
of hair growth, an effective amount of a pyrethroid, e.g., a type I
pyrethroid or, preferably, a type II pyrethroid, e.g.,
cypermethrin, deltamethrin, or fenvalerate. In a preferred
embodiment, the pyrethroid is administered topically. The
pyrethroid can be administered to the scalp, face, chest, legs, and
other regions of the body. In a preferred embodiment, the
pyrethroid is provided in a composition, e.g., a pharmaceutically
acceptable composition. In a preferred embodiment, the weight
percent of the pyrethroid ranges from 0.005% to 5%; the weight
percent of the pyrethroid ranges from 0.01% to 2%. In a preferred
embodiment, the compound is administered at any point in a hair
cycle, e.g., in the anagen (growth) phase of hair growth; in the
telogen (resting) phase of hair growth; in the catagen (the period
between the telogen phase and the anagen phase) phase of hair
growth.
[0003] In a preferred embodiment, the method includes: identifying
a subject in need of hair growth promoting treatment; after
administration of a pyrethroid compound, evaluating the effect of
the administration on hair growth; the treatment can involve more
than one administration, e.g., at least two, three, or four
administrations, of the pyrethroid compound.
[0004] In a preferred embodiment, the subject can be male or female
that suffers from genetic pattern baldness; suffers from a hormonal
disorder which decreases hair growth; has received a treatment,
e.g., radiation, or chemotherapy, or a drug which inhibits hair
growth; or has had a surgical procedure, e.g., skin graft, which is
in need of hair growth.
[0005] In another aspect, the invention features, a method of
promoting hair growth. The method includes administering to a
subject, e.g., a human with an insufficient amount of hair or an
insufficient rate of hair growth, an effective amount of a compound
of the formula: 1
[0006] in which each of R.sup.a, R.sup.b, R.sup.c, and R.sup.d,
independently, is H, fluoro, chloro, bromo, iodo, or C.sub.1-4
alkyl. Alkyl can be either a straight or branched group. Some
examples of alkyl groups are methyl, ethyl, propyl, isopropyl,
butyl, isobutyl, and tert-butyl. R.sup.2 is CN or C.ident.CH; and
R.sup.3 is 2
[0007] in which X is O, S, NH, or CH.sub.2; and each of R' and R",
independently, is H, fluoro, chloro, bromo, iodo, or C.sub.1-4
alkyl. The compound can exist as a salt, e.g., a hydrochloride
salt. There can be more than one substituents on each aromatic
ring, e.g., more than one R.sup.d, R', or R" on each ring.
[0008] In a preferred embodiment, the compound is administered
topically. The compound can be administered to the scalp, face,
chest, legs, and other regions of the body. In a preferred
embodiment, the compound is provided in a composition, e.g., a
pharmaceutically acceptable composition. In a preferred embodiment,
the compound is administered at any point in a hair cycle, e.g., in
the anagen (growth) phase of hair growth; in the telogen (resting)
phase of hair growth; in the catagen (the period between the
telogen phase and the anagen phase) phase of hair growth.
[0009] In a preferred embodiment, R.sup.2 is CN. In a preferred
embodiment, R.sup.1 is 3
[0010] in which each of R.sup.a, R.sup.b and R.sup.c,
independently, is H, fluoro, chloro, bromo, iodo, or C.sub.1-4
alkyl. In a preferred embodiment, each of R.sup.a and R.sup.b
independently, is chloro or bromo; and R.sup.c is H. In a preferred
embodiment, each of R.sup.a and R.sup.b, independently, is chloro;
X is O; and each of R' and R", independently, is H. In a preferred
embodiment, each of R.sup.a and R.sup.b, independently, is bromo; X
is O and each of R' and R" , independently, is H. In a preferred
embodiment, R.sup.1 is 4
[0011] in which R.sup.d is H, fluoro, chloro, bromo, iodo, or
C.sub.1-4 alkyl. In a preferred embodiment, R.sup.d is chloro; X is
O; and each of R' and R", independently, is H. In a preferred
embodiment, X is O; each of R' and R", independently, is H.
[0012] In a preferred embodiment, the method includes: identifying
a subject in need of hair growth promoting treatment; after
administration of an effective amount of the compound, evaluating
the effect of the administration on hair growth; the treatment can
involve more than one administration, e.g., at least two, three, or
four administrations, of the compound.
[0013] In a preferred embodiment, the subject can be male or female
that suffers from genetic pattern baldness; suffers from a hormonal
disorder which decreases hair growth; has received a treatment,
e.g., radiation, or chemotherapy, or a drug which inhibits hair
growth; or has had a surgical procedure, e.g., skin graft, which is
in need of hair growth.
[0014] The invention also includes composition of the compound
described herein. Accordingly, in another aspect, the invention
features, a composition for promoting hair growth. The preparation
can include a pyrethroid, e.g., a type I pyrethroid or, preferably,
a type II pyrethroid (e.g., cypermethrin, deltamethrin, or
fenvalerate), and a pharmaceutically acceptable carrier. In a
preferred embodiment, the composition is sterile. In a preferred
embodiment, the composition includes a fragrance. In a preferred
embodiment, the weight percent of the pyrethroid in the composition
ranges from 0.005% to 5%; the weight percent of the compound in the
composition ranges from 0.01% to 2%. In a preferred embodiment, the
compound is administered at any point in a hair cycle, e.g., in the
anagen (growth) phase of hair growth; in the telogen (resting)
phase of hair growth; in the catagen (the period between the
telogen phase and the anagen phase) phase of hair growth.
[0015] In another aspect, the invention features, a kit for
promoting hair growth. The kit includes, a compound described
herein and instruction for use of the compound to promote hair
growth.
[0016] In another aspect, the invention features, a container which
includes a compound described herein, wherein the container has one
ore more of the following properties: it contains less than 5.0,
1.0, 0.5, or 0.1 g of the compound described herein; it is air
tight; it is waterproof; or in addition to the compound described
herein, it contains a fragrance or other cosmetic ingredient.
[0017] By promoting hair growth is meant an increase in the total
mass of hair or the total length of the hairs, in a unit area,
e.g., per cm.sup.2, as compared to nontreated tissue. It can
include one or more of: an increase in the length or growth rate of
a hair shaft, an increase in the number of hairs, or an increase in
the thickness of a hair. In a preferred embodiment, the growth rate
is increased.
[0018] Unless otherwise defined, all technical and scientific terms
used herein have the same meaning as commonly understood by one of
ordinary skill in the art to which this invention belongs. Although
methods and materials similar or equivalent to those described
herein can be used in the practice or testing of the present
invention, suitable methods and materials are described below. All
publications mentioned herein are incorporated by reference in
their entirety. In case of conflict, the present specification,
including definitions, will control. In addition, the materials,
methods, and examples are illustrative only and not intended to be
limiting.
[0019] Other features or advantages of the present invention will
be apparent from the following detailed description of several
embodiments, and also from the appending claims.
DETAILED DESCRIPTION
[0020] Methods of the invention relate to a composition for
promoting hair growth which contains a pyrethroid compound, e.g., a
type I or type II pyrethroid compound, as an active ingredient.
Preferred compounds are type II compounds. Type I pyrethroid
compounds (e.g., permethrin) differ from type II pyrethroid
compounds (e.g., cypermethrin) in that type II compounds possess a
cyano group on the .alpha.-carbon atom of the phenoxybenzyl moiety.
Some examples of type II pyrethroid compounds present in the
composition of this invention are cypermethrin, deltamethrin, and
fenvalerate.
[0021] Another aspect of this invention features a composition
having a compound of formula (I) as an active ingredient. 5
[0022] in which each of R.sup.a, R.sup.b, R.sup.c, and R.sup.d,
independently, is H, fluoro, chloro, bromo, iodo, or C.sub.1-4
alkyl; R.sup.2 is CN or C.ident.CH; and R.sup.3 is 6
[0023] in which X is O, S, NH, or CH.sub.2; and each of R' and R",
independently, is H, fluoro, chloro, bromo, iodo, or C.sub.1-4
alkyl. The compounds described above exhibit geometrical and
optical isomerism. For example, geometrical isomerism can result
from the configuration of different substituents on the cyclopropyl
ring with respect to one another and the ring. Optical isomerism
can arise from different arrangement of the substituents on the
carbon atom attaching to the .alpha.-cyano or the .alpha.-ethynyl
group. Both optically active and racemic mixtures of pyrethroid
compounds (or their salts) can be employed in the composition of
this invention.
[0024] The compounds described above can be synthesized according
to procedures known in the art, e.g., by transesterification or
Wittig reaction. A detailed description of the preparation of the
pyrethroid compounds can be found in U.S. Patent No. 4,024,163.
[0025] A pharmaceutical composition containing a compound described
herein in an effective amount can be used to promote hair growth.
The compositions can be used to treat alopecia (including
androgenic alopecia, e.g., male pattern baldness, and alopecia
areata). The use of such a composition for the manufacture of a
medicament for promoting hair growth is also within the scope of
this invention.
[0026] Still another aspect of this invention is a method of
promoting hair growth by administering to a subject an effective
amount of a compound described herein.
[0027] An effective amount of the composition of the present
invention is defined as the amount of the composition which, upon
administration to an animal in need, confers a hair
growth-promoting effect on treated animals. The effective amount to
be administered to an animal is typically based on a variety of
factors including age, sex, surface area, weight, and conditions of
the animal. Body surface area may be approximately determined from
height and weight of the patient. See, e.g., Scientific Tables,
Geigy Pharmaceuticals, Ardley, N.Y., 1970, 537. An effective amount
of a compound described herein in the composition of this
invention, i.e., doses, e.g., daily doses, can range from about
0.01 mg/kg to about 25 mg/kg; from about 0.1 mg/kg to about 12.5
mg/kg. Effective doses will also vary, as recognized by those
skilled in the art, dependant on route of administration, excipient
usage, and the possibility of co-usage with other treatments such
as usage of other hair growth-promoting compounds.
[0028] The pharmaceutical composition may be administered via the
parenteral route, including orally, topically, subcutaneously,
intraperitoneally, intramuscularly, intranasally, and
intravenously. Topical administration is preferred. Repeated
administration of the composition, e.g., repeated topical
administration, can be used. More than one route of administration
can be used simultaneously, e.g., topical administration in
association with oral administration. Examples of parenteral dosage
forms include aqueous solutions of the active agent, in a isotonic
saline, 5% glucose or other well-known pharmaceutically acceptable
excipient. Solubilizing agents such as cyclodextrins, or other
solubilizing agents well-known to those familiar with the art, can
be utilized as pharmaceutical excipients for delivery of the hair
growth-promoting composition.
[0029] The composition of this invention can also be formulated
into dosage forms for other routes of administration utilizing
conventional methods. A pharmaceutical composition can be
formulated, for example, in dosage forms for oral administration in
a capsule, a tablet (each including timed release and sustained
release formulations), or a gel seal. Capsules may comprise any
standard pharmaceutically acceptable material such as gelatin or
cellulose derivatives. Tablets may be formulated in accordance with
the conventional procedure by compressing mixtures of pyrethroid
compounds and a solid carrier, and a lubricant. Examples of solid
carriers include starch and sugar bentonite. The hair
growth-promoting composition can also be administered in a form of
a hard shell tablet or capsule containing, for example, lactose or
mannitol as a binder and a conventional filler and a tableting
agent.
[0030] Topical administration of the hair growth-promoting
compounds described herein presents an attractive route of
administration amongst the many different routes described above.
Such topical pharmaceutical compositions can exist in many forms,
e.g., in the form of a solution, cream, ointment, gel, lotion,
shampoo, or aerosol formulation adapted for application to the
skin. The weight percent of the active ingredient in the
composition, i.e., the pyrethroid compound, useful in promoting
hair growth ranges from 0.01% to 5% (based on the total weight of
the composition) in admixture with a pharmaceutically acceptable
carrier. A wide variety of carrier materials can be employed in the
hair growth-promoting composition of this invention such as
alcohols, aloe vera gel, allantoin, glycerine, vitamin A and E
oils, mineral oils, and polyethylene glycols. Other additives,
e.g., fragrance or other cosmetic ingredients, can be present in
the composition.
[0031] The following specific examples, which describe the hair
growth-compositions of this invention and biological testings of
such compositions, are to be construed as merely illustrative, and
not limitative of the remainder of the disclosure in any way
whatsoever.
EXAMPLE 1
[0032] The following example was performed to determine if
pyrethroid compounds cause skin irritation (as indicated by ear
thickness in mice). Skin irritants may contribute to promoting hair
growth.
[0033] Prior to the experiment, ear thickness of mice (C3H strain,
female, 16 weeks of age, n=3/group) was measured with a thickness
gage (Mitsutoyo Corp.). After measuring ear thickness of both ears,
10 .mu.L of ethanol was applied on left ear and 10 .mu.L of a
pyrethroid solution (1% pyrethroid compound in ethanol) was applied
to the right ear. Ear thickness was measured for three consecutive
days after administration. The results of left and right ear
thickness are tabulated in Table 1 below:
1 TABLE 1 day 0 1 2 3 Left Ear Group I Ethanol only 27.7 27.7 27.3
27.7 (.times.0.01 mm) SD 0.58 0.58 0.58 1.15 Group II Ethanol only
27.0 27.3 27.3 27.7 (.times.0.01 mm) SD 0 0.58 0.58 0.58 Group III
Ethanol only 27.3 28.3 27.7 27.3 (.times.0.01 mm) SD 0 1.15 1.15
0.58 Group IV Ethanol only 27.3 27.7 27.3 28.0 (.times.0.01 mm) SD
0.58 0.58 0.58 1.00 Right Ear Group I Cypermethrin 27.7 27.7 27.3
28.0 (.times.0.01 mm) SD 0.58 0.58 0.58 1.00 Group II Deltamethrin
27.0 27.3 27.3 28.0 (.times.0.01 mm) SD 0 0.58 0.58 1.00 Group III
Fenvalerate 27.3 28.0 28.0 27.0 (.times.0.01 mm) SD 0.58 1.00 1.73
1.00 Group IV Permethrin 27.3 27.7 27.7 28.3 (.times.0.01 mm) SD
0.58 0.58 0.58 1.15
[0034] As can be seen from Table 1 above, the pyrethroid-containing
compositions, i.e., the compositions containing cypermethrin,
deltamethrin, fenvalerate, or permethrin did not increase ear
thickness when compared to ethanol. In other words, all four
compositions tested did not have primary irritancy at a
concentration of 1% in ethanol.
EXAMPLE 2
[0035] Another ear thickness experiment was performed. Ear
thickness of mice (Sencar strain, female, 10 weeks of age, n
=3/group) was measured with a thickness gage (Mitsutoyo Corp.).
After measuring the thickness of both ears at the beginning of the
experiment, 20 .mu.L of 12-O-tetradecanoyl-phorbol 13-acetate (TPA)
at a concentration of 10.sup.-4 M in acetone was applied on both
ears, followed by the application of 10 .mu.L of ethanol on the
left ears and 10 .mu.L of the four compositions tested in Example 1
on the right ears (at a concentration of 1% of pyrethroid compound
in ethanol solution). Again, ear thickness was monitored over three
consecutive days following administration of the compositions. The
results are provide in Table 2.
2 TABLE 2 day 0 1 2 3 Left Ear Group I Ethanol only 24.0 27.7 28.3
28.3 (.times.0.01 mm) SD 1.00 28.0 2.52 1.53 Group II Ethanol only
26.0 28.0 29.0 29.0 (.times.0.01 mm) SD 2.65 0.58 2.00 1.73 Group
III Ethanol only 24.0 27.3 29.0 28.3 (.times.0.01 mm) SD 0 1.53
1.00 0.58 Group IV Ethanol only 23.7 29.7 27.7 28.0 (.times.0.01
mm) SD 0.58 3.06 2.08 1.73 Right Ear Group I Cypermethrin 24.0 26.7
28.3 27.3 (.times.0.01 mm) SD 1.00 0.58 2.31 0.58 Group II
Deltamethrin 26.0 27.3 29.0 28.0 (.times.0.01 mm) SD 2.65 0.58 2.00
1.73 Group III Fenvalerate 24.0 26.3 26.7 26.7 (.times.0.01 mm) SD
1.00 0.58 0.58 0.58 Group IV Permethrin 23.3 27.3 27.0 27.7
(.times.0.01 mm) SD 0.58 1.53 0 0.58
[0036] As was seen in Example 1, the compositions tested failed to
cause skin irritation, as compared to ethanol.
EXAMPLE 3
[0037] This experiment was conducted to test the skin irritancy of
the compositions of this invention on hair-growing areas of test
subjects, i.e., female mice (10 weeks old) of the C3H strain (n=5
group). After clipping the hair of the back skin of mice with an
electric clipper, 5 .mu.L/cm.sup.2 of each four composition tested
in Examples 1 and 2 (at a concentration of 1% in an ethanol
solution) were applied. The application was administered once a
day, for 3 consecutive days. Skin irritation was evaluated by
unaided visual inspection at the end of the third day. The level of
irritation was scored as follows:
[0038] -: no irritation
[0039] .+-.: weak irritation
[0040] +: clear irritation
[0041] ++: strong irritation
[0042] The results are presented in Table 3.
3 TABLE 3 Concentration after 72 hours Group I 1% in ethanol --
Cypermethrin Group II 1% in ethanol -- Deltamethrin Group III 1% in
ethanol -- Fenvalerate Group IV 1% in ethanol -- Permethrin
[0043] Based on the results in Table 3, the four compositions,
i.e., the compositions containing cypermethrin, deltamethrin,
fenvalerate, and permethrin, all failed to cause skin irritation
(redness) with three repeated topical administration to mice skin
at a concentration of 1% in ethanol.
EXAMPLE 4
[0044] The ability of topical administration of pyrethroid
compounds to promote hair growth was assessed in female C3H strain
mice (10 weeks old; n=5/group). Hair on the back skin of the mice
was clipped carefully with an electric clipper. 5 .mu.L/cm.sup.2 of
the five compositions tested in the examples above were applied to
the mice daily. The level of hair growth at the applied skin areas
were evaluated by unaided visual inspection at the indicated time.
Cyclosporin A was used as a control. The results are shown in Table
4.
4 TABLE 4 Day 7 14 19 29 36 Group I Cypermethrin 1% 0 0 2 4 5
Ethanol 0 0 0 0 0 Group II Deltamethrin 1% 0 0 1 5 5 Ethanol 0 0 0
0 0 Group III Fenvalerate 1% 0 0 1 4 4 Ethanol 0 0 0 0 0 Group IV
permethrin 1% 0 0 0 0 0 Ethanol 0 0 0 0 0 Cyclosporin A 1% 0 5 5 5
5 Ethanol 0 0 0 0 0
[0045] The results showed that the compositions containing
cypermethrin, deltamethrin, and fenvalerate were effective in
promoting hair growth. New hair growth occurred at areas of the
skin where the compositions were applied.
EXAMPLE 5
[0046] The experiment described in Example 4 was repeated with a
commercially available hair growth-promoting compound (5%
minoxidil) as a control. The results are shown in Table 5.
5 TABLE 5 Week 1 2 3 4 5 6 Group I Cypermethrin 1% 0 0 5 5 5 5 0.1%
0 0 5 5 5 5 0.01% 0 0 0 0 0 0 Ethanol 0 0 0 0 0 0 Group II
Deltamethrin 1% 0 2 5 5 5 5 0.1% 0 0 5 5 5 5 0.01% 0 0 1 1 1 3
Ethanol 0 0 0 0 1 1 Group III Fenvalerate 1% 0 0* 3* 5 5 5 0.1% 0 0
5 5 5 5 0.01% 0 0 0 0 0 0 Ethanol 0 0 0 0 0 0 Group IV Permethrin
1% 0 0 0 0 0 1 0.1% 0 0 0 0 0 0 0.01% 0 0 0 0 0 0 Ethanol 0 0 0 0 0
0 Minoxidil 5% 0 0 2 3 4 4 Ethanol 0 0 0 0 0 0 *skin color of 2 out
of 5 mice was lightened; no hair growth was observed at the
indicated time period
[0047] The results above showed that the three compositions
containing cypermethrin, deltamethrin, and fenvalerate were
effective in promoting hair growth at concentrations of 0.1% and 1%
in ethanol solutions. New hair growth occurred at areas of the skin
where the compositions were applied. Moreover, the hair growth
potency was dose dependent.
OTHER EMBODIMENTS
[0048] From the above description, one skilled in the art can
ascertain the essential characteristics of the present invention,
and without departing from the spirit and scope thereof, can make
various changes and modifications of the invention to adapt it to
various usages and conditions. For example, the hair
growth-promoting compositions of the invention can contain two or
more pyrethroid compounds. Thus, other embodiments are also within
the claims.
* * * * *